New drug aims to shrink liver fat and prevent scarring in fatty liver disease
NCT ID NCT07024212
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests an injection called DR10624 in 110 adults with fatty liver disease (MASLD) who are at high risk of liver fibrosis (scarring). The study is split into two parts: Part 1 checks if the drug reduces liver fat and fibrosis risk, while Part 2 focuses on safety in a related condition. Participants are randomly assigned to receive either DR10624 or a placebo, and neither they nor their doctors know which they get.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DR10624 injection (a drug being tested to reduce liver fat and fibrosis)
What this could lead to
If successful, this could point toward a new treatment option for people with fatty liver disease who are at high risk of liver scarring.
What could go wrong
This is an early Phase II trial with only 110 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Gulou Hospital
Nanjing, China
-
Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
-
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, China
-
The First Hospital of Jilin University
Changchun, China